CLEVELAND -- ZipGen, Inc. announces the availability for sale of gene amplification primers that are used in the rapid detection of severe acute respiratory syndrome (SARS).
Gene amplification primers provide a fast and reliable method for health agencies, hospitals, and laboratories to detect the presence of the SARS coronavirus in patients. The primers are used with a highly sensitive technology known as polymerase chain reaction (PCR), which rapidly detects the SARS virus from patient samples. The primers can be used for samples from sputum, blood, urine, and fecal matter. With conventional serology being too slow, the SARS epidemic marks the first time in the history of infectious diseases where genetic diagnostics based upon gene amplification has been proven to be the fastest means of detecting the presence of the SARS virus.
ZipGen, Inc. is part of the expanding list of biotechnology-based firms to address the needs of the global medical community in the rapid detection of this newly emergent pathogen. As the world health community copes with this recent deadly disease, new, reliable, and rapid technologies such as these primers will allow for better detection and control of this crisis.
ZipGen, Inc.'s nand existing products include specialty primers for the SARS virus, Mycobacterium tuberculosis, non-tuberculous mycobacterial diseases, foodborne pathogens and custom primers. According to the World Health Organization (WHO) ruberculosis is the single biggest killer of people living with HIV/AIDS (PLWH). The ZipLys Buffer provides a format for cell lysis for nucleic acid extraction from a broad spectrum of bacterial cell types. The ZipLys Myco and ZipLys Bacto Systems are integrated formats that enable isolation, cultivation and nucleic acid extraction from Mycobacterium tuberculosis, atypical Mycobacterium, Nocardia, E. coli and other bacterial cells.
Source: ZipGen, Inc.
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.